title: Diabetes and dyslipidemia. A new model for transplant coronary artery disease.
abstract: BACKGROUND
  Clinical observations suggest that transplant coronary artery disease (TxCAD) is immunologically mediated but may be accelerated by metabolic derangements. We developed a rat model of heterotopic heart transplantation in the presence of diabetes and dyslipidemia to further study their role in TxCAD development.
  
  
  RESULTS
  Major histocompatibility complex-mismatched strains of inbred rats underwent heterotopic heart transplantation (ACI-to-Lewis allografts). Diabetes (DM) was induced by streptozotocin injection (80 mg/kg) after transplantation; dyslipidemia was worsened by feeding of a 60% high-fructose diet (+F). Allograft transplants were divided into four groups: (1) +DM/+F; (2) +DM/-F; (3) -DM/+F; and (4) -DM/-F. Isograft transplants (Lewis to Lewis, +DM/+/-F) were controls. All animals received daily cyclosporine (5 mg/kg). Grafts surviving > 30 days were evaluated for TxCAD on histological sections and graded 0 to 5 for intimal thickness. All streptozotocin-treated animals were diabetic within 2 weeks, with fourfold increases in plasma glucose concentrations versus nondiabetics. Severe TxCAD was observed in diabetic allografts only. The mean grade of TxCAD in diabetic allografts was 3.2 +/- 0.5 versus 1.1 +/- 0.4 in diabetic isografts (P < 0.03) and zero TxCAD in nondiabetic allografts (P < or = 0.0001). Fructose feeding resulted in a 1.5-fold higher triglyceride and a 1.3-fold higher cholesterol level versus the regular diet (-F) but showed no independent contribution to the development of TxCAD.
  
  
  CONCLUSIONS
  These findings suggest that metabolic derangements associated with diabetes play an important role in TxCAD development in heterotopic ACI-to-Lewis rat heart transplantation. In this model of TxCAD in major histocompatibility complex-mismatched, diabetic, and dyslipidemic rats, immunologic and metabolic mechanisms that contribute to TxCAD can be further delineated and approaches to its prevention assessed.
authors.affiliation: Division of Cardiovascular Medicine, Stanford University, Calif., USA.
authors.forename: K
authors.initials: K
authors.lastname: Hoang
authors.forename: Y D
authors.initials: YD
authors.lastname: Chen
authors.forename: G
authors.initials: G
authors.lastname: Reaven
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: H
authors.initials: H
authors.lastname: Ross
authors.forename: M
authors.initials: M
authors.lastname: Billingham
authors.forename: H
authors.initials: H
authors.lastname: Valantine
mesh_terms: D000818:Animals; D001835:Body Weight; D003327:Coronary Disease / Q000209:etiology*; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D004195:Disease Models, Animal; D005632:Fructose / Q000494:pharmacology; D006084:Graft Rejection; D016027:Heart Transplantation / Q000009:adverse effects*; D008055:Lipids / Q000097:blood*; D008297:Male; D051381:Rats; D011912:Rats, Inbred ACI; D011917:Rats, Inbred Lew; D013311:Streptozocin
chemical_list: D008055:Lipids; D005632:Fructose; D013311:Streptozocin